Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Retrieved on:
Monday, November 9, 2020
Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
Key Points:
- Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
- Status epilepticus is associated with irreversible neurologic damage and death, both of which largely depend on the seizure duration before initial treatment, stated Barry Frankel, Chief Business Officer and co-founder of Sedor.
- SESQUIENT the first and only FDA-approved room temperature stable fosphenytoin could help health care providers quickly treat status epilepticus patients and potentially reduce hospital costs associated with this condition.
- The companys lead product, SESQUIENT, has received FDA approval for the treatment of status epilepticus.